115 related articles for article (PubMed ID: 34432457)
21. [Antiviral Drugs Targeting Influenza Virus Surface Proteins: A Computational Structural Biology Approach].
Igarashi M
Yakugaku Zasshi; 2015; 135(9):1015-21. PubMed ID: 26329546
[TBL] [Abstract][Full Text] [Related]
22. Lack of selective resistance of influenza A virus in presence of host-targeted antiviral, UV-4B.
Warfield KL; Schaaf KR; DeWald LE; Spurgers KB; Wang W; Stavale E; Mendenhall M; Shilts MH; Stockwell TB; Barnard DL; Ramstedt U; Das SR
Sci Rep; 2019 May; 9(1):7484. PubMed ID: 31097731
[TBL] [Abstract][Full Text] [Related]
23. Structure-activity relationship analysis of curcumin analogues on anti-influenza virus activity.
Ou JL; Mizushina Y; Wang SY; Chuang DY; Nadar M; Hsu WL
FEBS J; 2013 Nov; 280(22):5829-40. PubMed ID: 24034558
[TBL] [Abstract][Full Text] [Related]
24. An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
Hu Y; Musharrafieh R; Ma C; Zhang J; Smee DF; DeGrado WF; Wang J
Antiviral Res; 2017 Apr; 140():45-54. PubMed ID: 28087313
[TBL] [Abstract][Full Text] [Related]
25. Thiosialoside-decorated polymers use a two-step mechanism to inhibit both early and late stages of influenza virus infection.
Yu Y; Qin HJ; Shi XX; Song JQ; Zhou JP; Yu P; Fan ZC; Zhong M; Yang Y
Eur J Med Chem; 2020 Aug; 199():112357. PubMed ID: 32428793
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of drug resistance of hemagglutinin of influenza virus and potent scaffolds inhibiting its function.
Yanagita H; Yamamoto N; Fuji H; Liu X; Ogata M; Yokota M; Takaku H; Hasegawa H; Odagiri T; Tashiro M; Hoshino T
ACS Chem Biol; 2012 Mar; 7(3):552-62. PubMed ID: 22217114
[TBL] [Abstract][Full Text] [Related]
27. An Oleanolic Acid Derivative Inhibits Hemagglutinin-Mediated Entry of Influenza A Virus.
Ye M; Liao Y; Wu L; Qi W; Choudhry N; Liu Y; Chen W; Song G; Chen J
Viruses; 2020 Feb; 12(2):. PubMed ID: 32085430
[TBL] [Abstract][Full Text] [Related]
28. The Short Form of the Zinc Finger Antiviral Protein Inhibits Influenza A Virus Protein Expression and Is Antagonized by the Virus-Encoded NS1.
Tang Q; Wang X; Gao G
J Virol; 2017 Jan; 91(2):. PubMed ID: 27807230
[TBL] [Abstract][Full Text] [Related]
29. Identification of Novel Fusion Inhibitors of Influenza A Virus by Chemical Genetics.
Lai KK; Cheung NN; Yang F; Dai J; Liu L; Chen Z; Sze KH; Chen H; Yuen KY; Kao RY
J Virol; 2015 Dec; 90(5):2690-701. PubMed ID: 26676787
[TBL] [Abstract][Full Text] [Related]
30. Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication.
Perwitasari O; Yan X; O'Donnell J; Johnson S; Tripp RA
Assay Drug Dev Technol; 2015 Dec; 13(10):638-49. PubMed ID: 26192013
[TBL] [Abstract][Full Text] [Related]
31. Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses.
Hu Y; Zhang J; Musharrafieh RG; Ma C; Hau R; Wang J
Antiviral Res; 2017 Sep; 145():103-113. PubMed ID: 28778830
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of influenza virus activity by multivalent glycoarchitectures with matched sizes.
Papp I; Sieben C; Sisson AL; Kostka J; Böttcher C; Ludwig K; Herrmann A; Haag R
Chembiochem; 2011 Apr; 12(6):887-95. PubMed ID: 21384484
[TBL] [Abstract][Full Text] [Related]
33. T160A mutation-induced deglycosylation at site 158 in hemagglutinin is a critical determinant of the dual receptor binding properties of clade 2.3.4.4 H5NX subtype avian influenza viruses.
Gao R; Gu M; Liu K; Li Q; Li J; Shi L; Li X; Wang X; Hu J; Liu X; Hu S; Chen S; Peng D; Jiao X; Liu X
Vet Microbiol; 2018 Apr; 217():158-166. PubMed ID: 29615249
[TBL] [Abstract][Full Text] [Related]
34. Shift in oligosaccharide specificities of hemagglutinin and neuraminidase of influenza B viruses resistant to neuraminidase inhibitors.
Mochalova L; Bright R; Xu X; Korchagina E; Chinarev A; Bovin N; Klimov A
Glycoconj J; 2010 Apr; 27(3):321-7. PubMed ID: 20195900
[TBL] [Abstract][Full Text] [Related]
35. Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005.
Barr IG; Hurt AC; Iannello P; Tomasov C; Deed N; Komadina N
Antiviral Res; 2007 Feb; 73(2):112-7. PubMed ID: 16963130
[TBL] [Abstract][Full Text] [Related]
36. Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.
Triana-Baltzer GB; Sanders RL; Hedlund M; Jensen KA; Aschenbrenner LM; Larson JL; Fang F
J Antimicrob Chemother; 2011 Jan; 66(1):15-28. PubMed ID: 21097900
[TBL] [Abstract][Full Text] [Related]
37. The L46P mutant confers a novel allosteric mechanism of resistance toward the influenza A virus M2 S31N proton channel blockers.
Musharrafieh R; Lagarias PI; Ma C; Tan GS; Kolocouris A; Wang J
Mol Pharmacol; 2019 Aug; 96(2):148-157. PubMed ID: 31175183
[TBL] [Abstract][Full Text] [Related]
38. Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral.
Hu Y; Zhang J; Musharrafieh R; Hau R; Ma C; Wang J
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885544
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, Structure Activity Relationship and Anti-influenza A Virus Evaluation of Oleanolic Acid-Linear Amino Derivatives.
Li W; Yang F; Meng L; Sun J; Su Y; Shao L; Zhou D; Yu F
Chem Pharm Bull (Tokyo); 2019 Nov; 67(11):1201-1207. PubMed ID: 31434835
[TBL] [Abstract][Full Text] [Related]
40. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
